Literature DB >> 14015822

Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. II. Lymphoma 6C3HED cells cultured in a medium devoid of L-asparagine lose their susceptibility to the effects of guinea pig serum in vivo.

J D BROOME.   

Abstract

Cells of the original line of lymphoma 6C3HED, which regularly prove susceptible to the effects of guinea pig serum in vivo, were cultured in Eagle's medium devoid of L-asparagine; after a latent period of 2 or more weeks, during which time the cell population declined markedly, some of the cells began to proliferate, and thereafter continued vigorous growth. On implantation into mice the proliferating cells were found, however, to have completely and permanently lost their susceptibility to the effects of guinea pig serum. By contrast, when cultures of the original line of 6C3HED cells were prepared in Eagle's medium to which L-asparagine was added in a concentration of 20.0 mg/liter or more, they proliferated vigorously from the beginning; after long periods of growth in the enriched medium in vitro they remained susceptible to the effects of guinea pig serum upon test in vivo. Other amino acids, purines, and pyrimidines were unable to substitute for L-asparagine in this relation. Furthermore, a variant subline of 6C3HED cells which had become insensitive to guinea pig serum under in vivo conditions did not require L-asparagine for growth in tissue culture. It seems plain from the findings as a whole, that in 6C3HED cells, L-asparagine dependence in vitro is associated with the in vivo character of guinea pig serum sensitivity, and conversely L-asparagine independent variants are insusceptible to the effects of guinea pig serum. The implications of the findings complement those of a companion paper in which direct evidence is provided that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects.

Entities:  

Keywords:  ASPARAGINE; LYMPHOMA; PEPTIDE PEPTIDOHYDROLASES

Mesh:

Substances:

Year:  1963        PMID: 14015822      PMCID: PMC2137577          DOI: 10.1084/jem.118.1.121

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  16 in total

1.  The amino acid requirements of the Jensen sarcoma in vitro.

Authors:  T A McCOY; M MAXWELL; P F KRUSE
Journal:  Cancer Res       Date:  1959-07       Impact factor: 12.701

2.  Differences in inositol requirements of several strains of HeLa, conjunctival and amnion cells.

Authors:  R S CHANG
Journal:  Proc Soc Exp Biol Med       Date:  1958-10

3.  Amino acid requirements of the Novikoff hepatoma in vitro.

Authors:  T A McCOY; M MAXWELL; P F KRUSE
Journal:  Proc Soc Exp Biol Med       Date:  1959-01

4.  Isolation of a nutritional variant from a culture of rabbit fibroblasts.

Authors:  R F HAFF; H E SWIM
Journal:  Science       Date:  1957-06-28       Impact factor: 47.728

5.  Myo-Inositol as an essential growth factor for normal and malignant human cells in tissue culture.

Authors:  H EAGLE; V I OYAMA; M LEVY; A E FREEMAN
Journal:  J Biol Chem       Date:  1957-05       Impact factor: 5.157

6.  The utilization of glutamine, glutamic acid, and ammonia for the biosynthesis of nucleic acid bases in mammalian cell cultures.

Authors:  N P SALZMAN; H EAGLE; E D SEBRING
Journal:  J Biol Chem       Date:  1958-02       Impact factor: 5.157

7.  Isolation of nutritional variants from conjunctival and HeLa cells.

Authors:  R S CHANG
Journal:  Proc Soc Exp Biol Med       Date:  1957-12

8.  Dual requirement of Walker carcinosarcoma 256 in vitro for asparagine and glutamine.

Authors:  R E NEUMAN; T A MCCOY
Journal:  Science       Date:  1956-07-20       Impact factor: 47.728

9.  Studies on the free amino acids and related compounds in the tissues of the cat.

Authors:  H H TALLAN; S MOORE; W H STEIN
Journal:  J Biol Chem       Date:  1954-12       Impact factor: 5.157

10.  Studies on yeast metabolism. I. Fractionation and microdetermination of cell carbohydrates.

Authors:  W E TREVELYAN; J S HARRISON
Journal:  Biochem J       Date:  1952-01       Impact factor: 3.857

View more
  37 in total

1.  Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift.

Authors:  Jason R Cantor; Tae Hyeon Yoo; Aakanksha Dixit; Brent L Iverson; Thomas G Forsthuber; George Georgiou
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-05       Impact factor: 11.205

2.  Amino acid and vitamin requirements in mammalian cultured cells.

Authors:  K Yamamoto; A Niwa
Journal:  Amino Acids       Date:  1993-02       Impact factor: 3.520

3.  Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4.

Authors:  Reuven J Schore; Meenakshi Devidas; Archie Bleyer; Gregory H Reaman; Naomi Winick; Mignon L Loh; Elizabeth A Raetz; William L Carroll; Stephen P Hunger; Anne L Angiolillo
Journal:  Leuk Lymphoma       Date:  2019-01-10

4.  Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response.

Authors:  Akito Nakamura; Tadahiro Nambu; Shunsuke Ebara; Yuka Hasegawa; Kosei Toyoshima; Yasuko Tsuchiya; Daisuke Tomita; Jun Fujimoto; Osamu Kurasawa; Chisato Takahara; Ayumi Ando; Ryuichi Nishigaki; Yoshinori Satomi; Akito Hata; Takahito Hara
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-30       Impact factor: 11.205

5.  Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.

Authors:  Anne L Angiolillo; Reuven J Schore; Meenakshi Devidas; Michael J Borowitz; Andrew J Carroll; Julie M Gastier-Foster; Nyla A Heerema; Taha Keilani; Ashley R Lane; Mignon L Loh; Gregory H Reaman; Peter C Adamson; Brent Wood; Charlotte Wood; Hao W Zheng; Elizabeth A Raetz; Naomi J Winick; William L Carroll; Stephen P Hunger
Journal:  J Clin Oncol       Date:  2014-10-27       Impact factor: 44.544

6.  [In vitro studies using E. coli L-asparaginase on lymphatic cells of bovine leukemia and various transplantation tumors].

Authors:  W D Hirschmann; S Seeber; P Warnecke
Journal:  Klin Wochenschr       Date:  1969-11-15

Review 7.  [L-asparaginase and leukemia].

Authors:  E Grundmann
Journal:  Klin Wochenschr       Date:  1969-01-15

8.  Conditions for the production of L-asparaginase 2 by coliform bacteria.

Authors:  M H Bilimoria
Journal:  Appl Microbiol       Date:  1969-12

9.  [Inhibition of malignant human neoplasms with L-asparaginase].

Authors:  H F Oettgen; H K Schulten
Journal:  Klin Wochenschr       Date:  1969-01-15

10.  The human asparaginase-like protein 1 hASRGL1 is an Ntn hydrolase with beta-aspartyl peptidase activity.

Authors:  Jason R Cantor; Everett M Stone; Lynne Chantranupong; George Georgiou
Journal:  Biochemistry       Date:  2009-11-24       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.